Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and management

被引:7
作者
Baker, William F., Jr. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Hlth Sci Ctr, Los Angeles, CA 90095 USA
[2] California Clin Thrombosis Ctr, Bakersfield, CA 93311 USA
[3] Kern Med Ctr, Thrombosis Hemostasis & Special Hematol Clin, Bakersfield, CA 93305 USA
[4] Loyola Univ Chicago, Dept Pathol & Pharmacol, Maywood, IL 60153 USA
[5] Loyola Univ Chicago, Dept Cardiovasc Surg, Maywood, IL 60153 USA
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTERNATIONAL CONSENSUS STATEMENT; ANTI-PROTHROMBIN ANTIBODIES; OF-THE-LITERATURE; ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA; CLINICAL-SIGNIFICANCE; GLYCOPROTEIN-I; BETA(2)-GLYCOPROTEIN I; ANTICOAGULANT ACTIVITY;
D O I
10.1016/j.hoc.2007.10.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
While much is understood concerning the clinical features of patients with antiphospholipid syndrome (APS), many issues remain. The proper designation of patients with "definite" APS and the correct categorization of patients by both laboratory and clinical features are matters of ongoing debate. Recent proposals have identified new subsets of patients who have many typical features of APS but either do not fit die criteria for a "definite" diagnosis or have initially negative laboratory tests for antiphospholipid antibodies. Meanwhile, decisions about laboratory tests are based on expert opinion, rather than the results of controlled trials. As for treatment, many guidelines are offered, but few are backed by data from strong clinical trials. This article summarizes the clinical questions remaining to be answered and debates concerning pathogenesis, diagnosis, and management.
引用
收藏
页码:155 / +
页数:21
相关论文
共 89 条